Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007–18-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007–18

Published:2016-09 Issue:9 Volume:35 Page:1588-1594
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Divino Victoria¹,DeKoven Mitch²,Kleinrock Michael³,Wade Rolin L.⁴,Kaura Satyin⁵

Affiliation:

1. Victoria Divino ( ) is a senior consultant at IMS Health in Fairfax, Virginia.

2. Mitch DeKoven is a principal at IMS Health.

3. Michael Kleinrock is director of research development for the IMS Institute for Healthcare Informatics, in Parsippany, New Jersey.

4. Rolin L. Wade is a senior principal at IMS Health.

5. Satyin Kaura is a senior director at Celgene Corporation, in Summit, New Jersey.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference21 articles.

1. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years

2. The Economics of Orphan Drug Policy in the US

3. The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?

4. Are payers treating orphan drugs differently?

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status and Future Prospects of Diagnosis and Treatment for Rare Diseases;Advances in Clinical Medicine;2024

2. Trends, lag and characteristics of orphan drug approvals in the USA and China, 1983-2022;2023-12-02

3. Disentangling the Cost of Orphan Drugs Marketed in the United States;Healthcare;2023-02-13

4. Budget Impact Analysis of High-priced Orphan Medicinal Products intended for the treatment of Rare Diseases in China: Evidence from a densely populated metropolis of Chengdu;2022-11-01

5. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025;Orphanet Journal of Rare Diseases;2022-10-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3